QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

JBIO

QT68Jade Biosciences, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
16.82
-0.05-0.30%
OverviewShort InterestFilings
JBIOQT68Jade Biosciences, Inc.·NASDAQ
OverviewShort InterestFilings
16.82-0.30%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own8.22%
Shs Outstand59.35M
Perf Week4.60%
Market Cap550.40MForward P/E-EPS next Y-2.61Insider Trans0.00%Shs Float-Perf Month-23.13%
Enterprise Value495.99MPEG-EPS next Q-0.66Inst Own-Short Float-Perf Quarter19.46%
Income-73202861.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y4.86%
Sales-P/B3.29EPS next Y0.49%ROA-40.57%Short Interest-Perf YTD9.01%
Book/sh4.99P/C-EPS next 5Y-ROE-51.34%52W High28.00 -39.93%Perf Year102.90%
Cash/sh5.24P/FCF-EPS past 3/5Y-ROIC-44.96%52W Low6.67 152.17%Perf 3Y-
Dividend Est.-EV/EBITDA-3.83Sales past 3/5Y-Gross Margin0.00%Volatility5.12% 6.04%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM97.63%Oper. Margin0.00%ATR (14)1.59Perf 10Y-
Dividend Ex-DateApr 29, 2025Quick Ratio14.29Sales Y/Y TTM-Profit Margin0.00%RSI (14)41.22Recom2.00
Dividend Gr. 3/5Y-Current Ratio14.29EPS Q/Q-533.33%SMA20-6.96%Beta1.65Target Price44.33
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA50-20.72%Rel Volume5.04Prev Close16.87
Employees50LT Debt/Eq0.00EarningsAug 12SMA20014.79%Avg Volume949.93KPrice16.82
IPO DateApr 29, 2025Option/ShortYes / YesEPS/Sales Surpr.-9.62% -Net Debt/EBITDA0.42Volume4,785,274Change-0.30%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-15-26InitiatedUBSBuy$45
Jun-02-26ReiteratedPiper Sandler$55
Jun-02-26ReiteratedGuggenheimBuy$32 → $47
May-11-26ReiteratedWedbushOutperform$34
May-11-26ReiteratedGuggenheimBuy$14 → $32
Apr-27-26ReiteratedH.C. Wainwright$35 → $45
Mar-06-26ReiteratedStifel Nicolaus$19 → $40
Jan-07-26InitiatedH.CBuy$25
Oct-09-25InitiatedBTIGBuy$28
Jun-16-25UpgradeGuggenheimNeutral → Buy$14
Latest News
Jun-15-26
Jun-15-2608:55AM
UBS Initiates Coverage On Jade Biosciences with Buy Rating, Announces Price Target of $45Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit
000
Selling, General and Administrative Excl. Other202117
Research and Development935364
Other Operating Expense100
Operating Income-114-75-81
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)14-5-6
Net Income Before Taxes-127-70-75
Income Taxes
000
Consolidated Net Income-127-70-76
Net Income From Continuing Operations-127-70-76
Net Income-127-70-76
EPS (Recurring)-4.06-85.26-100.38
EPS (Basic, Before Extraordinaries)-4.06-85.26-100.38
EPS (Diluted)-4.06-85.26-100.38
EBITDA-127-69-75
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding3111
Market Capitalization478——
Operating Lease Expense
———
Insider Trading Volume
$18.16$16.24$14.32$12.40$10.48● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Frohlich TomChief Executive OfficerMay 16 '25Buy7.406,00044,4006,000May 19 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR